Inmune Bio Incis A Clinical Stage Biotechnology Company Based In Boca Ratonfloridafounded In 2015The Company Focuses On Developing Innovative Treatments That Target The Innate Immune System To Address Diseases Such As Cancer And Alzheimer Sinmune Bio Went Public On February 42019And Is Listed On Nasdaq Under The Ticker Symbol Inmb The Company Has Several Product Platforms Aimed At Modulating The Innate Immune Systemthe Dominant Negative Tumor Necrosis Factordn Tnfplatform Includes Candidates Like Xpro1595Which Is In Clinical Trials For Mild Alzheimer S Disease And Treatment Resistant Depressionthe Natural Killernkcell Priming Platformknown As Inkmuneis Designed To Enhance Nk Cell Activity Against Cancercurrently Being Tested For Metastatic Castration Resistant Prostate Canceradditionallythe Cordstrom Platform Utilizes Human Umbilical Cord Derived Stem Cells And Has Completed Trials For Recessive Dystrophic Epidermolysis Bullosainmune Bio Is Also Advancing Inb03 In Phase Ii Trials For Breast Cancer Treatmentthe Company Collaborates With Various Entities In The Biotechnology And Healthcare Sectorsincluding Xencorinc And The University Of Pittsburghto Further Its Research And Development Efforts
No conferences found for this company.
| Company Name | Inmune Bio Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
